ESR1 and breast cancer: In 2004, Olivotto believed that PR was meaningless in BC treatment decisions and only needed to consider the expression of ER because nearly 100% of BC patients in their cohort had ER expression consistent with PR expression and should stop PR testing in BC therapy [19].